Cargando…
Is Hematopoietic Stem Cell Transplantation Required to Unleash the Full Potential of Immunotherapy in Acute Myeloid Leukemia?
From monoclonal antibodies (mAbs) to Chimeric Antigen Receptor (CAR) T cells, immunotherapies have enhanced the efficacy of treatments against B cell malignancies. The same has not been true for Acute Myeloid Leukemia (AML). Hematologic toxicity has limited the potential of modern immunotherapies fo...
Autores principales: | Abadir, Edward, Gasiorowski, Robin E., Silveira, Pablo A., Larsen, Stephen, Clark, Georgina J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7073661/ https://www.ncbi.nlm.nih.gov/pubmed/32085578 http://dx.doi.org/10.3390/jcm9020554 |
Ejemplares similares
-
Examination of CD302 as a potential therapeutic target for acute myeloid leukemia
por: Lo, Tsun-Ho, et al.
Publicado: (2019) -
CD300f epitopes are specific targets for acute myeloid leukemia with monocytic differentiation
por: Abadir, Edward, et al.
Publicado: (2019) -
Measurable Residual Disease in Acute Myeloid Leukemia Using Flow Cytometry: A Review of Where We Are and Where We Are Going
por: Dix, Caroline, et al.
Publicado: (2020) -
Electroporation and Immunotherapy—Unleashing the Abscopal Effect
por: Justesen, Tobias Freyberg, et al.
Publicado: (2022) -
Current status of hematopoietic stem cell transplant in chronic myeloid leukemia
por: Gupta, Alok, et al.
Publicado: (2014)